SG11202009588PA - PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS - Google Patents
PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTSInfo
- Publication number
- SG11202009588PA SG11202009588PA SG11202009588PA SG11202009588PA SG11202009588PA SG 11202009588P A SG11202009588P A SG 11202009588PA SG 11202009588P A SG11202009588P A SG 11202009588PA SG 11202009588P A SG11202009588P A SG 11202009588PA SG 11202009588P A SG11202009588P A SG 11202009588PA
- Authority
- SG
- Singapore
- Prior art keywords
- prodrugs
- bicyclic
- fused
- c5ar antagonists
- c5ar
- Prior art date
Links
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 title 1
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862651512P | 2018-04-02 | 2018-04-02 | |
| PCT/US2019/025165 WO2019195159A1 (en) | 2018-04-02 | 2019-04-01 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202009588PA true SG11202009588PA (en) | 2020-10-29 |
Family
ID=68054774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202009588PA SG11202009588PA (en) | 2018-04-02 | 2019-04-01 | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20190300526A1 (en) |
| EP (1) | EP3773563A4 (en) |
| JP (1) | JP7337833B2 (en) |
| KR (1) | KR20200139751A (en) |
| CN (1) | CN111954525B (en) |
| AR (1) | AR114464A1 (en) |
| AU (1) | AU2019246969A1 (en) |
| BR (1) | BR112020019822A2 (en) |
| CA (1) | CA3095184A1 (en) |
| IL (1) | IL277608B2 (en) |
| MA (1) | MA52245A (en) |
| MX (1) | MX2020010390A (en) |
| SG (1) | SG11202009588PA (en) |
| TW (1) | TWI827590B (en) |
| WO (1) | WO2019195159A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10562896B2 (en) | 2017-05-31 | 2020-02-18 | Chemocentryx, Inc. | 6-5 fused rings as C5a inhibitors |
| KR102586710B1 (en) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | 5-5 fused ring as C5a inhibitor |
| CA3073956A1 (en) | 2017-09-03 | 2019-03-07 | Angion Biomedica Corp. | Vinylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors |
| EP3728203B1 (en) * | 2017-12-22 | 2024-03-13 | ChemoCentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| EP3728202A4 (en) | 2017-12-22 | 2021-05-26 | ChemoCentryx, Inc. | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors |
| US20190300526A1 (en) | 2018-04-02 | 2019-10-03 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
| US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| BR112022009192A2 (en) | 2019-12-19 | 2022-07-26 | Active Biotech Ab | COMPOSITION, METHOD TO TREAT AN EYE DISEASE OR EYE DISORDER, AND, USE OF A COMPOUND |
| JP2023513272A (en) * | 2020-02-07 | 2023-03-30 | ガシャーブラム・バイオ・インコーポレイテッド | heterocyclic GLP-1 agonists |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| US20220047592A1 (en) * | 2020-08-13 | 2022-02-17 | Chemocentryx, Inc. | METHODS OF TREATING RESPIRATORY DISEASES USING C5a INHIBITORS |
| AU2022371727A1 (en) | 2021-10-22 | 2024-05-02 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing tetracyclic compound, preparation method therefor, and medical use thereof |
| CN113666985A (en) * | 2021-10-22 | 2021-11-19 | 山东谷雨春生物科技有限公司 | Preparation method of triamcinolone acetonide |
| CN116023321A (en) * | 2022-12-30 | 2023-04-28 | 中国药科大学 | STING inhibitor prodrug and medical application thereof |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| GB8613591D0 (en) | 1986-06-04 | 1986-07-09 | Roussel Lab Ltd | Chemical compounds |
| FR2761266B1 (en) * | 1997-03-28 | 1999-07-02 | Sanofi Sa | PHARMACEUTICAL COMPOSITION FORMED BY WET GRANULATION FOR THE ORAL ADMINISTRATION OF A DERIVATIVE OF N-PIPERIDINO-3- PYRAZOLECARBOXAMIDE, ITS SALTS AND THEIR SOLVATES |
| EP1320531B1 (en) | 2000-08-10 | 2010-09-08 | Pfizer Italia S.r.l. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| JP5260818B2 (en) | 2000-09-29 | 2013-08-14 | ノバルティス・インターナショナル・ファーマシューティカル・リミテッド | High affinity low molecular weight C5a receptor modulator |
| SE524438C2 (en) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Remote controlled door-related locking arrangement, first and second computer program products, carrying medium and a computer-soluble medium |
| JP4196678B2 (en) | 2001-04-26 | 2008-12-17 | 味の素株式会社 | Heterocyclic compounds |
| DE10231787A1 (en) | 2001-07-19 | 2003-02-06 | Luk Lamellen & Kupplungsbau | Clutch release for motor vehicle transmission has master cylinder and slave cylinder with additional electrically controlled valve to control clutch locking when stationary |
| ITMI20012025A1 (en) | 2001-09-28 | 2003-03-28 | Dompe Spa | QUATERNARY AMMONIUM SALTS OF OMEGA-AMINO ALKYLAMIDS OF R 2-ARY-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| JP2006508894A (en) | 2002-03-28 | 2006-03-16 | ニューロジェン・コーポレーション | Substituted tetrahydroisoquinolines as C5A receptor modulators |
| WO2003082826A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| JP2005530719A (en) | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| US7166619B2 (en) | 2002-08-14 | 2007-01-23 | Ppd Discovery , Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7145012B2 (en) * | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| US7906528B2 (en) | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| US20100035875A1 (en) | 2008-06-20 | 2010-02-11 | Bing-Yan Zhu | Triazolopyridine jak inhibitor compounds and methods |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| PT3078658T (en) | 2008-12-22 | 2019-07-16 | Chemocentryx Inc | C5ar antagonists |
| CN102595897A (en) | 2009-09-02 | 2012-07-18 | 默沙东公司 | Aminotetrahydropyrans as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| ES2632975T3 (en) | 2010-06-24 | 2017-09-18 | Chemocentryx, Inc. | C5aR antagonists |
| US8846656B2 (en) * | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| EP2885304B8 (en) | 2012-08-16 | 2016-12-07 | Janssen Pharmaceutica NV | Pyrrolopyrazoles as n-type calcium channel blockers |
| CN103421006B (en) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-tetra-substituted dihydro pyrazol hexahydropyridine derivant and its preparation method and application |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| KR102395093B1 (en) * | 2016-04-04 | 2022-05-04 | 케모센트릭스, 인크. | Soluble C5aR antagonists |
| KR102586710B1 (en) | 2017-05-31 | 2023-10-10 | 케모센트릭스, 인크. | 5-5 fused ring as C5a inhibitor |
| US10562896B2 (en) | 2017-05-31 | 2020-02-18 | Chemocentryx, Inc. | 6-5 fused rings as C5a inhibitors |
| EP3728202A4 (en) | 2017-12-22 | 2021-05-26 | ChemoCentryx, Inc. | Diaryl substituted 5,5-fused ring compounds as c5ar inhibitors |
| EP3728203B1 (en) | 2017-12-22 | 2024-03-13 | ChemoCentryx, Inc. | DIARYL SUBSTITUTED 6,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| US20190300526A1 (en) | 2018-04-02 | 2019-10-03 | Chemocentryx, Inc. | PRODRUGS OF FUSED-BICYCLIC C5aR ANTAGONISTS |
-
2019
- 2019-04-01 US US16/371,627 patent/US20190300526A1/en not_active Abandoned
- 2019-04-01 KR KR1020207031483A patent/KR20200139751A/en active Search and Examination
- 2019-04-01 CN CN201980024914.2A patent/CN111954525B/en active Active
- 2019-04-01 AR ARP190100863A patent/AR114464A1/en unknown
- 2019-04-01 SG SG11202009588PA patent/SG11202009588PA/en unknown
- 2019-04-01 MX MX2020010390A patent/MX2020010390A/en unknown
- 2019-04-01 IL IL277608A patent/IL277608B2/en unknown
- 2019-04-01 AU AU2019246969A patent/AU2019246969A1/en active Pending
- 2019-04-01 WO PCT/US2019/025165 patent/WO2019195159A1/en unknown
- 2019-04-01 JP JP2020553520A patent/JP7337833B2/en active Active
- 2019-04-01 MA MA052245A patent/MA52245A/en unknown
- 2019-04-01 CA CA3095184A patent/CA3095184A1/en active Pending
- 2019-04-01 BR BR112020019822-6A patent/BR112020019822A2/en unknown
- 2019-04-01 US US16/982,817 patent/US11608336B2/en active Active
- 2019-04-01 EP EP19782402.2A patent/EP3773563A4/en active Pending
- 2019-04-02 TW TW108111647A patent/TWI827590B/en active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3773563A1 (en) | 2021-02-17 |
| AR114464A1 (en) | 2020-09-09 |
| IL277608B2 (en) | 2023-09-01 |
| KR20200139751A (en) | 2020-12-14 |
| US20210052612A1 (en) | 2021-02-25 |
| AU2019246969A1 (en) | 2020-10-15 |
| MX2020010390A (en) | 2021-01-15 |
| TWI827590B (en) | 2024-01-01 |
| JP2021519794A (en) | 2021-08-12 |
| BR112020019822A2 (en) | 2021-03-16 |
| IL277608B1 (en) | 2023-05-01 |
| CN111954525B (en) | 2023-12-26 |
| WO2019195159A1 (en) | 2019-10-10 |
| MA52245A (en) | 2021-04-28 |
| RU2020135500A (en) | 2022-05-05 |
| CN111954525A (en) | 2020-11-17 |
| US11608336B2 (en) | 2023-03-21 |
| TW202002966A (en) | 2020-01-16 |
| IL277608A (en) | 2020-11-30 |
| CA3095184A1 (en) | 2019-10-10 |
| JP7337833B2 (en) | 2023-09-04 |
| EP3773563A4 (en) | 2021-12-29 |
| US20190300526A1 (en) | 2019-10-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL277608B1 (en) | Prodrugs of fused-bicyclic c5ar antagonists | |
| CA187858S (en) | Tapered cup | |
| ZA201806632B (en) | Soluble c5ar antagonists | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| CA184556S (en) | Tapered cup | |
| GB201905552D0 (en) | Antagonists | |
| IL283627A (en) | Improved delivery of large agents | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| IL262921B (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| SG11202002207QA (en) | Trpv2 antagonists | |
| GB201810746D0 (en) | Use of sclerostin antagonist | |
| GB201815629D0 (en) | Antagonists | |
| GB201820458D0 (en) | Ox1 antagonists | |
| GB2575067B (en) | Selection of identifiers | |
| IL281448A (en) | Prodrugs of cgrp antagonists | |
| IL276107A (en) | Solid forms of fasoracetam | |
| GB201718256D0 (en) | Ox1 antagonists | |
| IL283413A (en) | Antagonists | |
| PT3755833T (en) | Thread structure | |
| GB201803632D0 (en) | Non-combustible thread | |
| IL258446B (en) | Thread restorationtool | |
| GB201808741D0 (en) | Use of TRPA1 antagonists | |
| SI3511335T1 (en) | Manufacture of metallasilisesquioxanes | |
| GB201810835D0 (en) | Methods of use | |
| GB201721386D0 (en) | Chrondogy of time-wave |